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Cefsulodin for the treatment of Pseudomonas 
infections -  a study comparing cefsulodin 
and ticarcillin
J.W .M . van der M eer, A. M atze-van der Lans and  H. M attie
Department of Infectious Diseases, University Hospital, Leiden 
(Received 15 April 1988; revision received 15 September 1988; accepted 8 October 1988)
The efficacy of cefsulodin against infections caused by Pseudomonas aeruginosa 
was investigated first in an open trial and then in a controlled comparative study in 
which ticarcillin was used. The first trial consisted of 16 patients with proven 
Pseudomonas aeruginosa infections, 9 of whom also received an aminoglycoside. In 
the second trial 28 such patients were evaluated (14 on cefsulodin 1 g 4 times daily 
and 14 on ticarcillin 5 g 4 times daily); all patients also received an aminoglycoside. 
The results of the two trials were similar in that 75% of the patients of the first trial 
and 86% of the second group exhibited an excellent or good response to cefsulodin. 
For the ticarcillin group a similar response was noted. In the first trial the sensitivity 
of P. aeruginosa did not change markedly, whereas one strain of the cefsulodin group 
became resistant in the second trial. Pharmacokinetic data were in agreement with 
those reported in the literature. Side effects were rare. Neth J Med 1989; 34:233- 242.
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Introduction
Cefsulodin is a cephalosporin antibiotic with distinctive in vitro and in vivo 
activity against Pseudomonas aeruginosa [1,2]. Theoretically, this antibiotic has 
several advantages over other antibiotics with anti-Pseudomonas activity. First of all, 
it acts selectively against P. aeruginosa. Although this makes cefsulodin unsuitable 
for empirical therapy in serious infections, it is to be preferred in proven Pseudo-
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monas infections because all other anU-Pseudonionas drugs have a broader spectrum 
of antimicrobial activity. Secondly, compared to ticarcillin, the sodium load of 
cefsulodin therapy is negligible and the latter drug does not adversely affect platelet 
function. In order to investigate the efficacy of cefsulodin against infections caused 
by P. aeruginosa, an open trial among patients with severe Pseudomonas infections 
and then a controlled comparative study using ticarcillin were carried out. The aim 
of the latter part of the study was to establish whether cefsulodin is at least as 
efficacious as ticarcillin for the treatment of P. aeruginosa infections.
Materials and Methods
Patients
Twenty-two patients with suspected or proven infections caused by P. aeruginosa 
entered the first non-comparative trial after giving informed consent; only those 
who had not undergone previous anti-Pseudomonas treatment were eligible. This 
trial was part of an early multicentre trial of cefsulodin (Clinical report, Ciba-Geigy). 
The drug was given at a dosage of 1 g 4 times daily i.v.
In the second trial 28 patients with proven Pseudomonas infections were ran­
domized to receive either cefsulodin (dosage: 1 g 4 times daily i.v.) or ticarcillin 
(dosage: 5 g 4 times daily i.v.), both in combination with tobramycin or netilmicin 
(dosage: 2 m g/kg  3 times daily and 3 m g/kg  3 times daily, respectively, adjusted 
for renal impairment if necessary). The latter drug was given to patients with 
preexisting substantial renal insufficiency or deafness. The dose of cefsulodin was 
adjusted to marked renal insufficiency in only four patients (two in the first and two 
in the second trial). Only those patients who had not received prior Pseudo­
monas therapy, were included in this study, after having given informed consent; 
moreover the P. aeruginosa had to be sensitive to at least one of the beta-lactam 
antibiotics.
Sensitivity testing
In vitro sensitivity was tested by inoculation of a 1 :1000 dilution of an 18-h 
culture on Isosensitest agar in a two-fold dilution series. Sensitivity was defined by 
an MIC for cefsulodin <^16 mg/1 and for ticarcillin ^  128 mg/1.
Evaluation of efficacv
Clinical criteria. At the end of treatment the clinical response was scored as 
excellent (cure), good (significant improvement), fair (some improvement) or poor 
(no improvement).
Bacteriological criteria. The bacteriological response was scored as elimination of 
the pathogen, reduction of the number of pathogens, no quantitative or qualitative 
change, or replacement by a different pathogen.
TABLE 1
Patient characteristics: open trial.
Age
(yr)
Sex Infectious condition Medical history
58 M Wound infection Renal t ra n sp lan t/  
surgery of ureter
76 F Cystitis --
43 M Ecthyma gangrenosum N on-H odgkin’s lymphoma
52 F Pleural empyema Bronchial carcinoma, lobectomy
56 M Cholangitis After cholecystectomy
49 M Septicaemia +  sinusitis Hairy cell leukaemia
36 M Pneumonia Cystic fibrosis 
+ bronchiectasis
54 M Infected neoplastic skin lesions Hodgkin’s disease
78 M Urinary tract infection --
82 F Urinary tract infection --
31 M Preputial infection with chills Acute myeloid leukaemia
61 M Prostatitis --
20 F Bronchopneumonia Cystic fibrosis
59 M Lung abscess
21 M Bronchopneumonia Cystic fibrosis
20 F Bronchopneumonia Cystic fibrosis
* Patient died, due to infection.
Cefsulodin with ( + ) 
or without ( - )  
aminoglycoside
Response
clinical bacteriological
+
+
+
+
+
+
+
+
+
Good
Good
Good
Fair
Good
Good
Poor
Poor *
Excellent
Good
Excellent
Good
Good
Good
Poor
Good
Replacement 
( 5. epidermidis ) 
Elimination 
Elimination 
No change 
Replacement 
( K. pneumoniae ) 
Elimination 
Replacement 
( P. mirabilis )
No change
Elimination
Elimination
Elimination
Elimination
Replacement
( Pseudomonas sp. 
+ H. influenzae) 
Elimination 
Elimination 
Elimination
TABLE 2a
Results of treatment with cefsulodin: comparative trial.
Age Sex Infectious condition Medical history Aminoglycoside Response
(yr) (T = 
N =
tobramycin
netilmicin)
clinical bacteriological
48 M Pulmonary infiltrate Tonsillar carcinoma, 
resection lymph nodes
T Excellent Reduced
55 F Pneumonia Diabetes mellitus; myasthenic syndrome T Good Resistant
20 M Abscess in axilla Non-H odgkin’s lymphoma T Excellent No follow-up
66 M Otitis media Diabetes mellitus, N Poor No follow-up
cerebral vascular disease
69 M Urinary tract infection 
+  lower resp. tract inf.
Cardiac & renal insufficiency; 
peptic ulcer
T Good Reduced
70 M Perichondritis -- N Good Elimination
75 M Pneumonia Postoperative (bifurcation prosthesis); 
chronic respiratory disease
T Good Elimination
67 M Colonization by 
Pseudomonas
N on-H odgkin’s lymphoma; granulocytopenia 
(granulocyte count < 0 . 5 x l 0 9/ 0
T Good Elimination
62 M Septicaemia Ileus; chronic lymphocytic leukaemia T Good Elimination
73 M Bronchopneumonia Postoperative (aortic valve prosthesis); 
pulmonary emphysema
T Fair Elimination
74 M Urinary tract infection Total hip replacement; diabetes T Good Replacement 
( Candida )
64 F Respiratory tract inf. Bronchiectasis; lobectomy ( l j  yr) T Good Elimination
67 M Chronic external otitis Angina pectoris N Excellent Elimination
56 M Septicaemia Leukopenia (recent chemotherapy); 
(granulocyte count < 1 . 0 x l 0 9/ l )  
thoracotomy
T Good No follow-up
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TABLE 2b
Results of treatment with ticarcillin: comparative trial.
Age
(yr)
Sex Infectious condition Medical history Aminoglycoside 
(T = tobramycin 
N = netilmycin)
Response
clinical bacteriological
43 M Perichondritis (left ear) Schizophrenia T Excellent No follow-up
84 F Pyelonephritis/septicaemia Cerebrovascular accident T Good Elimination
71 M Pneumonia Acute lymphocytic leukaemia, 
diabetes mellitus
T Good Reduced
36 M Urinary tract infection Hip prosthesis, renal transplant (5 yr) N Good Elimination
36 M Pneumonia Allogenic bone marrow transplantation T Poor No follow-up
50 F Perichondritis/ 
external otitis
Agranulocytosis; recurrent external 
otitis, perichondritis
N Excellent Elimination
76 F Pyelonephritis/septicaemia Diabetes mellitus; renal insufficiency N Excellent Replacement 
( Enterococcus )
80 M Cholangitis/bacteraem ia Pancreatic carcinoma T Good Elimination
71 M Pleural empyema Lobectomy; diabetes mellitus T Poor No change
67 M Urinary tract infection Surgery for subdural haematoma & 
empyema; impaired micturition
T Good Replacement 
( K. pneumoniae )
68 M Bronchopneumonia Respiratory insufficiency, chronic 
bronchitis; diabetes mellitus, 
sick sinus syndrome, cardiac failure
T Good Elimination
84 M External otitis Chronic bronchitis N Good Elimination
67 M Respiratory tract infection Bronchiectasis T Good Elimination
24 M Septicaemia Allogenic bone marrow transplantation T Good Replacement 
( S. epidermidis )
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Pharmacokinetics
In the first study blood samples were taken on one of the first few days of 
treatment with cefsulodin at 0, 1, 2, 3, 4, and 6 h and, if possible, 1 week later. 
Blood was collected in heparinized tubes and centrifuged; plasma was stored at 
-70  °C  until the assay. Cefsulodin concentrations were determined microbiologi- 
cally by agar diffusion, using a P. aeruginosa strain (10701) as test organism. The 
exponential elimination rate constant was calculated from the plasma concentra­
tions by the least-squares method. The concentration at zero time was calculated by 
extrapolation. The apparent volume of distribution was calculated by dividing the 
dose by the concentration at zero time. Total plasma clearance was calculated as the 
product of the volume of distribution and the elimination rate constant.
Results
First study
Of the 22 patients that entered the study, two were excluded because P. 
aeruginosa was not the cause of the infection. The MIC of cefsulodin was 2 to 
4 mg/1 in the majority of patients, but in a few' patients it was 8 or 16 mg/1. The 
efficacy could not be evaluated in four cases because of early death due to unrelated 
causes [3] and discontinuation of treatment because of side effects [1]. The diagnoses 
of the remaining 16 patients are given in Table 1.
Of these 16 patients, seven received only cefsulodin and nine were on combina­
tion therapy (cefsulodin plus tobramycin, in most cases). The clinical response was 
excellent in two, good in ten, fair in one and poor in three cases. One of the poor 
responders died (due to the P. aeruginosa infection). There was no difference in 
response between patients receiving cefsulodin alone and those on combination 
therapy (efficacy rate 5 /7  and 7 /9 , respectively).
As for the bacteriological response, the pathogen w'as eliminated in 10 of 16 
patients. Of the remaining six patients, two exhibited no change, while four had a 
different pathogen ( Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus epider- 
midis and Pseudomonas sp. together with Haemophilus influenzae) that had replaced 
the Pseudomonas aeruginosa. The sensitivity of P. aeruginosa did not decrease 
markedly during cefsulodin treatment in any of our patients. There was no relation 
between initial MIC and response.
Second study
Of the 28 patients, 14 were treated with cefsulodin and 14 with ticarcillin. Eleven 
in the cefsulodin group and ten in the ticarcillin group received combination therapy 
with tobramycin, the remainder were treated with netilmicin (see Materials and 
Methods). Patient characteristics are presented in Tables 2a and b. The two groups 
were similar as far as sex, age and underlying illness were concerned. In practically 
all patients the MIC for cefsulodin was 2 or 4 mg/1 and that for ticarcillin 8 or
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16 mg/1. For the cefsulodin group the clinical response was excellent in three, good 
in nine, fair in one and poor in one case. For the ticarcillin group the clinical results 
were similar: excellent in three, good in nine and poor in two cases; one of the poor 
responders, however, died of other causes during therapy. The bacteriological 
response in the cefsulodin-treated group was elimination of the pathogen in seven 
patients and reduction of the number of micro-organisms in two patients. In one 
case the Pseudomonas became resistant (MIC more than 64 mg/1); moreover a 
second micro-organism ( Proteus inconstans) was cultured from this patient's sputum. 
In a second case Candida albicans was cultured from urine after irradication of the 
Pseudomonas. No bacteriological follow-up was available for three patients. In the 
ticarcillin group P. aeruginosa was also eliminated in seven, decreased in one and 
unchanged in one case. In three patients Pseudomonas was replaced by a different 
micro-organism: Klebsiella pneumoniae, Enterococcus and Staphylococcus epider- 
midis. Bacteriological follow-up was not performed in two cases. Again there was no 
relation between initial MIC and response.
Side effects
Side effects were rare. One patient on cefsulodin developed thrombophlebitis at 
the site of the infusion catheter and another developed thrombocytopenia. In the 
latter case cefsulodin-dependent antibodies against platelets could be detected by 
the method of Claas et al. [3]. Both side effects were seen in the first study.
Pharmacokinetics
Using the data on 13 patients we were able to calculate the pharmacokinetic 
parameters for cefsulodin; in six cases, the plasma concentrations were measured on 
the first day of treatment and on the eighth day. Pertinent data are given in Table 3. 
In patients 1 and 14 the dose was adjusted to 600 and 750 mg 4 times daily, 
respectively. In all patients maximal concentrations ranged between 20 and 50 mg/1
-  except in patient 1, in whom maximal concentrations between 70 and 160 mg/1 
occurred -  and through concentrations of about 4 to 10 mg/1, without unwanted 
effects. The calculated plasma clearance correlated closely with the creatinine 
clearance, as calculated from body weight and plasma creatinine according to the 
method of Siersbaek-Nielsen [4] (Fig. 1). It can be seen that for all practical 
purposes cefsulodin plasma clearance may be regarded as being equal to creatinine 
clearance. The mean half life, as calculated from the mean elimination rate constant, 
was 2 h. There was no consistent change in pharmacokinetic parameters between 
the first day and one week later.
Discussion
The overall results of an open and a comparative trial on the treatment of P. 
aeruginosa infections with cefsulodin were remarkably similar. An excellent or good 
response was observed in at least 75% of the patients. In this respect our data 
corroborate those published earlier [5-7].
ITABLE 3
Pharmacokinetic parameters of cefsulodin in 13 patients.
Patient
number
Volume of 
distribution 
(1)
Volume per kg 
bodyweight 
(1/kg)
Elimination 
rate constant 
(h -1)
Cefsulodin
clearance
(m l/m in )
Creatinine
clearance
(m l/m in )
J i /2
(h)
1 15.7 * 0.37 * 0.104 * 26.9 * 17.4 * 6.66 *
2 15.7 0.26 0.195 50.9 59.7 3.55
5 27.0 * 0.57 * 0.268 * 104.5 * 94.0 2.59 *
6 25.3 0.39 0.557 243.9 86.2 1.25
7 21.2 * 0.35 * 0.436 * 153.8 * 137.5 * 1.59 *
11 22.6 * 0.43 * 0.301 * 113.0 * 128.9 * 2.30 *
14 18.9 * 0.35 * 0.270 * 83.9 * 36.9 * 2.57 *
16 18.3 * 0.27 * 0.305 * 92.9 * 65.8 * 2.27 *
18 47.0 0.82 0.279 218.1 69.8 2.49
19 16.6 0.43 0.591 163.1 106.5 1.17
20 20.9 * 0.34 * 0.318 * 109.5 * 107.7 * 2.18 *
21 19.3 0.34 0.373 120.1 153.1 1.86
22 11.6 0.27 0.568 109.4 96.0 1.22
mean 21.6 0.40 0.351 122.3 89.2 1.97 **
SD (8.7) (0.15) (0.149) (61) (39.2)
* Mean of values on two occasions.
* * Calculated from mean elimination rate constant.
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Creatinine clearance
Fig. 1. Relation between total plasma clearance of cefsulodin and creatinine clearance in patients treated 
for Pseudomonas infections. Open and closed symbols represent initial assessment and assessment 1 wk 
later, respectively. Symbols in parentheses were not used for calculation of the regression line.
The majority of patients in the present study took the beta-lactam drugs in 
combination with aminoglycosides. There were two reasons for this approach: 
namely to increase efficacy, whether by an additive or synergistic effect, and 
(possibly even more important) to prevent or at least delay emergence of resistance 
to the beta-lactam antibiotic. Our study does not clearly demonstrate an increased 
efficacy as a result of the addition of aminoglycosides. Interestingly, combination 
with aminoglycosides could not prevent the emergence of resistance in one patient; 
in this case the micro-organism became resistant to cefsulodin as well as ticarcillin.
Due to the strict inclusion criteria, i.e. only patients with proven Pseudomonas 
infections who had not been treated previously with a.nii-Pseudomonas drugs, the 
study was limited in size. Nevertheless, there were no indications that, for the
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treatment of Pseudomonas infections, cefsulodin with an aminoglycoside is less 
efficacious than ticarcillin with an aminoglycoside.
The criterion of a proven Pseudomonas infection may have caused some bias 
since some patients with a serious infectious condition were not included because 
empirical antibiotic therapy, including drugs active against P. aeruginosa, had 
already been given. However, since cefsulodin is an anti-Pseudomonas drug with a 
narrow spectrum, it should probably not be considered at all under these cir­
cumstances; broad spectrum antimicrobial drugs, such as ticarcillin, piperacillin, 
ceftazidime or imipenem, are then to be preferred.
Both cefsulodin and ticarcillin administration were remarkably free of side 
effects. This is partially due to patient selection. For example, patients with cardiac 
failure or severe renal impairment were not included in the randomized trial, 
although they were treated with cefsulodin.
The pharmacokinetic data on cefsulodin found in this study are in agreement 
with those published earlier [8].
In conclusion, cefsulodin, in combination with an aminoglycoside, is effective 
against Pseudomonas infections. In this respect it is not less efficacious than 
ticarcillin; it also offers the advantage of more selective action and a lower total 
dose, which could be favourable as far as side effects are concerned.
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